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Abstract
Background: Progestational agents may reduce the risk of preterm birth in women with various risk factors. We
sought to test the hypothesis that a weekly dose of 17-hydroxyprogesterone caproate (17P) given to women with
preterm rupture of the membranes (PROM) will prolong pregnancy and thereby reduce neonatal morbidity.
Methods: Double-blind, placebo-controlled randomized clinical trial. Women with PROM at 23.0 to 31.9 weeks of
gestation were randomly assigned to receive a weekly intramuscular injection of 17P (250 mg in 1 mL castor oil) or
placebo (1 mL castor oil). The primary outcome was the rate of continuing the pregnancy until 34.0 weeks of
gestation or until documentation of fetal lung maturity at 32.0 to 33.9 weeks of gestation. Planned secondary
outcomes were duration of latency period and rate of composite neonatal morbidity. Enrollment of 111
participants per group, 222 total, was planned to yield 80% power to detect an increase in the primary outcome
from 30% with placebo to 50% with 17P.
Results: Twelve women were enrolled of whom 4 were randomly assigned to receive 17P and 8 to receive
placebo. The trial was terminated prematurely because of two separate issues related to the supply of 17P. No
adverse events attributable to 17P were identified.
Conclusion: Because of premature termination, the trial does not have adequate statistical power to evaluate
efficacy or safety of 17P in women with PROM. Nonetheless, ethical principles dictate that we report the results,
which may contribute to possible future metaanalyses and systematic reviews.
Trial Registration: ClinicalTrials.gov: NCT01119963
Supported by a research grant from the Center for Research, Education, and Quality, Pediatrix Medical Group,
Sunrise, FL
Background
Preterm rupture of the membranes (PROM) occurs in
2-4% of singleton pregnancies, yet accounts for 18-20%
of perinatal mortality in the United States [1]. PROM is
frequently followed by preterm birth (PTB) within a few
days [1,2]. Management of PROM involves a weighing
of risks of prematurity complications versus risks of
prolonging the pregnancy, such as chorioamnionitis, pla-
cental abruption, or cord prolapse. With PROM before
32 weeks of gestation, the morbidity of PTB is high, so
attempts to prolong the pregnancy are generally advo-
cated [1,2], a strategy called “expectant management.”
With PROM after 34 weeks, or after 32 weeks if fetal
lung maturity is documented, the complications of PTB
are less and the risks of infection and other complica-
tions of expectant management remain, so delivery is
generally recommended [1,2].
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management of PROM are often unsuccessful. The rate
of delivery during expectant management of PROM
roughly follows a “half-life” function, with about half of
patients delivering within a week and about half of the
remainder delivering with each subsequent week [3-6].
Antibiotic prophylaxis after PROM has been shown to
prolong the latency period [3-7] (interval from PROM-
to-delivery) and reduce neonatal morbidity [6,7]. Toco-
lysis has not been shown to be effective after PROM
[8,9].
Progestational agents such as progesterone and 17-
hydroxyprogesterone caproate (17P) have been shown to
reduce the rate of PTB in women with certain risk fac-
tors for PTB, including women with a history of a prior
PTB [10-12], women with a short cervix [13-15], or
women who have had an acute episode of preterm labor
successfully suppressed after tocolysis [16,17]. It is
unknown whether 17P or other progestins might be
beneficial after PROM. Progestins have multiple actions
that might potentially help to prolong pregnancy after
PROM, including suppression of inflammatory media-
tors and decreased production of contraction-associated
proteins such as gap junction proteins and oxytocin
receptors [18]. Briery and colleagues reported a small
trial that showed no benefit of 17P versus placebo after
PROM [19], but only 35 subjects had actually received
17P, so statistical power to reach a negative conclusion
was rather limited.
The present study was undertaken to test the hypoth-
esis that 17P given to mothers with PROM before 32
weeks of gestation will prolong the pregnancy and
thereby reduce neonatal morbidity.
Methods
The trial was sponsored, designed, and conducted by the
Obstetrix Collaborative Research Network, a consortium
of maternal-fetal medicine practices across the United
States. The trial was approved by the independent Insti-
tutional Review Board (IRB) at each site. The study was
conducted under Investigational New Drug (IND) Num-
ber 107785 through the United States Food and Drug
Administration (FDA). The trial was registered on
http://clinicaltrials.gov, #NCT01119963. An independent
Data and Safety Monitoring Board (DSMB) supervised
the trial, reviewed adverse event reports, and approved
the premature termination of the trial. Additional File 1
contains the complete, IRB-approved, final protocol.
Women were eligible if they were at least 18 years old,
had a singleton pregnancy at 23.0 to 31.9 weeks of
gestation, and PROM. PROM was defined as either (a)
documentation of vaginal leakage of indigo carmine dye
instilled via amniocentesis; (b) a positive Amnisure
® test
(Amnisure International, Cambridge, MA); or (c) two or
more of the following: nitrazine test of vaginal secretions
with pH 7 or higher, ferning of vaginal secretions, gross
pooling of clear fluid in the posterior vaginal fornix, or
ultrasound exam showing oligohydramnios. We
excluded women with active preterm labor, defined as 8
or more uterine contractions per hour that were per-
ceived by the patient and/or a cervical dilation 4 cm or
more. The definition of PROM did not require that the
rupture of membranes had occurred before the onset of
labor (commonly called “premature” or “prelabor”
PROM); that is, women were eligible if they had labored
before PROM provided that they were not in active
labor, as defined, at the time of enrollment. We
excluded women with contraindications to expectant
management (such as suspected intraamniotic infection,
nonreassuring fetal heart rate tracing, fetal death, pree-
clampsia, active uterine bleeding, or documented fetal
lung maturity), with known fetal abnormalities (such as
major congenital malformation, viral infection, or
hydrops), with history of allergy to 17P or castor oil,
with medical conditions that might adversely interact
with 17P (such as asthma requiring medications, renal
insufficiency, seizure disorder, ischemic heart disease,
cholecystitis, impaired liver function, or history of
venous thromboembolism, breast cancer or depression
requiring hospitalization), with medical conditions trea-
ted with systemic steroid medications, or with a cervical
cerclage present at the time of PROM. Eligible women
were approached by a physician or research nurse and
were offered participation in the trial.
Women who gave informed consent were randomly
assigned in a 1:1 ratio to receive either 17P (250 mg in
castor oil, 1 mL total volume, intramuscular injection
weekly) or an identical-appearing placebo (1 mL castor
oil only). A computer-generated random-number
sequence was used by the trial statistician to generate a
randomization code book kept at each site’si n p a t i e n t
pharmacy. Study medications (17P versus placebo) were
prepared by McGuff Pharmaceuticals (Newport, Califor-
nia) according to the IND specifications, which followed
current Good Manufacturing Practices (cGMP). Medica-
tions were provided in 5 mL multi-dose vials, specially
labeled for the study and number-coded to correspond
with the randomization code book. Randomization was
stratified by gestational age, 23.0-25.9 weeks, 26.0 to
28.9 weeks, and 29.0 to 31.9 weeks. Participants and
research personnel were blinded to group assignment
throughout, from before enrollment until after comple-
tion of all case report forms and resolution of all data
queries. The code was not broken until after the data-
base was “locked.”
Each week from randomization until delivery, the
assigned medication (17P or placebo) was drawn into a
syringe labeled “Study medication: progesterone or
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ered to the nursing unit, and administered by a regis-
tered nurse. In the syringes, 17P and placebo appeared
visually identical.
Other than the administration of study medication
(17P or placebo), the remainder of each patient’s clinical
care followed standard clinical management for PROM.
The investigators agreed in advance on many items of
standard management. These included inpatient hospita-
lization of all patients until delivery, administration of a
single course of antenatal corticosteroids, broad-spec-
trum antibiotic prophylaxis for 1 week, avoidance of
tocolytics (except during the 48 h after the first dose of
corticosteroids), and fetal heart rate monitoring at least
1 h daily. We encouraged amniocentesis to rule-out
intraamniotic infection before enrollment, but did not
require this. We discouraged digital examination of the
cervix, but did not exclude subjects who had already
had digital examinations. The protocol called for collec-
tion of amniotic fluid from vaginal leakage at 32.0 weeks
or beyond for assessment of fetal lung maturity accord-
ing to whatever test was in use at the local site. Intra-
partum antibiotic prophylaxis (e.g. group B
streptococcus coverage) was encouraged but not man-
dated. A protocol was in place for evaluation and man-
agement of suspected membrane resealing, but this was
not used because all the participants continued leaking
amniotic fluid until delivery. Management decisions not
specifically addressed by protocol were left to the discre-
tion of the managing physician, including route of deliv-
ery, choice of antibiotics, and other matters.
The primary outcome was defined as prolongation of
the pregnancy until a favorable gestational age, which
we defined as either 34.0 weeks of gestation or docu-
mentation of fetal lung maturity at 32.0 to 33.9 weeks.
The investigators agreed that continuation of pregnancy
beyond these time points was not indicated. Secondary
outcomes were latency (interval from randomization to
delivery) and composite neonatal morbidity, which was
defined per Mercer et al. [6] as one or more of: still-
birth, neonatal death, infant death before hospital dis-
charge, respiratory distress syndrome (RDS), intracranial
hemorrhage (ICH) grade 3 or 4, necrotizing enterocolitis
(NEC) stage 2 or 3, culture-proven neonatal sepsis
within 72 h of birth. In addition to the components
defined by Mercer et al. [6], our definition of composite
neonatal morbidity included periventricular leukomala-
cia (characteristic lesions in the subcortical white matter
seen on cerebral imaging studies within 96 h of birth.)
Sample size calculations indicated that we would need
105 participants in each group (17P or placebo) to yield
80% power to detect a 20% absolute increase in the rate
of the primary outcome from 30% in the placebo group
to 50% in the 17P group. This was adjusted to 111 per
group to account for a possible 5% rate of loss-to-fol-
low-up due to membrane resealing or other factors. A
single interim analysis was planned when data were
available for 50% of the total sample, but this was not
performed owing to early termination of the study.
Because of early termination, the trial is grossly under-
powered; therefore, we present only descriptive statistics
by treatment group and we did not perform any formal
statistical tests of potential between-group differences.
The trial was designed, conducted, analyzed, and
reported according to the principles outlined in the
CONSORT Statement and Checklist [20].
Results
From October, 2010 through January, 2011, twelve par-
ticipants were enrolled, of whom 4 were randomly
assigned to receive 17P and 8 were assigned to receive
placebo. Figure 1 is a flow diagram showing the number
of women at each stage of the trial.
On December 28, 2010, the FDA sent a Warning Let-
ter [21] to McGuff Pharmaceuticals citing certain viola-
tions of cGMP in the company’s manufacturing facility.
Officials at McGuff disclosed this letter to us, stating
that it did not relate to the production of 17P or pla-
cebo for our trial because the study medications were
prepared in a segregated facility, not the general manu-
facturing line of the company cited in the Warning Let-
t e r .M c G u f fh a ds e n tp e r i o d i ca l i q u o t st oa n
independent testing laboratory to verify the potency,
sterility, and stability of the preparations throughout this
trial and our previous trials evaluating 17P in twin [22]
and triplet [23] pregnancies. Despite these reassurances,
our DSMB recommended that we seek specific guidance
from the FDA as to whether the Warning Letter
impacted our trial. The FDA Division of Reproductive
and Urologic Drug Products asked for copies of the doc-
umentation of the independent testing. Despite exten-
sive documentation that the samples were sterile, pure,
and stable, the FDA placed the trial on “Full Clinical
Hold” on January 24, 2011. At that time, two women
were still receiving study medications and we immedi-
ately discontinued any further administration of the
drugs to them. We stopped all further recruitment into
the study and notified all the local-site IRBs and the
DSMB. We returned all the study medications to
McGuff to be quarantined. We had planned to petition
the FDA to remove the clinical hold and then to resume
enrollment after McGuff had satisfactorily addressed the
concerns outlined in the Warning Letter.
On February 4, 2011, the FDA granted approval to
KV Pharmaceuticals to produce and distribute a for-
mulation of 17-hydroxyprogesterone caproate under
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FDA-approved formulation, an official at McGuff noti-
fied us that they would no longer be able to prepare
medications for our trial. We considered the option of
resuming the trial using Makena, but this would have
resulted in a “blended” trial with medications obtained
from 2 different sources. Although we had indepen-
dent testing suggesting that the McGuff preparation
was pure and stable, we felt that a blended trial would
always be plagued by questions about the validity of
combining subjects whose medications were obtained
from two distinctly different sources. Thus we elected
to terminate the present study and report the results.
This decision was reviewed and approved by the
DSMB.
Table 1 summarizes the baseline characteristics of
those in each group. Table 2 summarizes the primary
outcome and secondary outcomes related to pregnancy
prolongation. Table 3 summarizes neonatal outcomes.
Table 4 shows other outcomes of interest. Table 5 lists
the participating sites. Additional File 2 presents the de-
identified individual participant raw data.
There was one neonatal death in each group. In the
17P group, the mother experienced PROM at 23.7
weeks of gestation, was randomized at 24.0 weeks, was
diagnosed with chorioamnionitis 2 days later, and
underwent induction of labor. She delivered at 610 g
male infant who ultimately developed necrotizing enter-
ocolitis and died at 24 days of life. In the placebo group,
the mother had PROM at 19.9 weeks, was randomized
at 24.0 weeks and started spontaneous labor 8 days
later. The 1000 g male infant had severe respiratory dis-
tress and died shortly after birth.
Discussion
Because the trial was prematurely terminated, it is
obviously underpowered to m a k ec o n c l u s i o n sa st ot h e
efficacy or safety of 17P in women with PROM.
Figure 1 Flow diagram showing number of participants at each stage of trial.
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ious ethical dilemmas. As noted in an editorial in The
Lancet [24], “There is ... a moral responsibility to
ensure that the commitments shown by physicians to
their patients in the research setting and the commit-
ments made by patients to advance clinical knowledge
are not subject to the vagaries of commercial restruc-
turing.” Although vagaries in the manufacturing and
approval of 17P were the cause of our premature trial
termination, we were faced with the practical reality
that these circumstances made it impossible for us to
complete the trial using the formulation with which
we started.
Lievre et al. [25] stated that enrollment of a patient
into a research trial is “a moral contract by which the
study (the investigators, the scientists, and the sponsor)
agrees to use all possible means to make the patient’s
participation useful to the community.” Certainly, had
w ec h o s e nn o tt or e p o r tt h er e s u l t sf r o mt h e1 2s u b -
jects who enrolled, their participation would not have
been useful. Such a choice would not be ethically ten-
able. We have every confidence that those subjects
who were assigned to receive 17P actually received
pure, sterile 17P and that those assigned to placebo
actually received a pure, sterile preparation that was




(N = 4) (N = 8)
Maternal Age (years) 28 ± 3 33 ± 6
Gestational Age at PROM
(weeks)
25 ± 7 26 ± 4
Gestational Age at
Randomization (weeks)
28 ± 3 27 ± 3
23.0-25.9 wks 1 (25%) 4 (50%)
26.0-28.9 wks 1 (25%) 1
(12.5%)
29.0-31.9 wks 2 (50%) 3
(37.5%)
Interval from PROM to
Randomization (days)
3 (1-79) 1.5 (0-
29)
Prepregnancy Weight (pounds) 157 ± 35 162 ±
37
Body Mass Index (kg/M
2) 2 4±7 2 7±6
Body Mass Index > 30 kg/M
2 1 (25%) 3
(37.5%)
Nulliparous 3 (75%) 5
(62.5%)
History of Prior Preterm Birth 0 0
Progestins Used Prior to 15
Weeks
1 (25%) 2 (25%)
Conception
Spontaneous 3 (75%) 7
(87.5%)
In Vitro Fertilization 1 (25%) 0
Intrauterine Insemination 0 1
(12.5%)
Married/Living with Partner 3 (75%) 7
(87.5%)
College Education or More 1 (25%) 5
(62.5%)
Ethnicity
Caucasian 3 (75%) 6 (75%)
African-American 1 (25%) 1
(12.5%)
Native American 0 1
(12.5%)
Reported Antepartum Substance Use
Alcohol, Rare 0 1
(12.5%)
Marijuana 1 (25%) 1
(12.5%)
Tobacco 0 2 (25%)
Other 0 0
Results expressed as Mean ± SD, Median (range), or N (%).





(N = 4) (N = 8)
Primary Outcome
Delivery at 34.0 weeks or
more
00




Gestational Age at Delivery
(weeks)
30 ± 4 28 ± 3
Delivery before 32 weeks 2 (50%) 7 (87.5%)
Delivery before 34 weeks 4 (100%) 8 (100%)
Pulmonary Maturity Testing
Immature 1 (25%) 2 (25%)
Not Tested 3 (75%) 6 (75%)
Latency, Randomization to
Delivery (weeks)
1.6 ± 1.0 1.3 ± 1.6
Less than 1 week 1 (25%) 5 (62.5%)
1.0 to 1.9 weeks 1 (25%) 1 (12.5%)
2.0 weeks or more 2 (50%) 2 (25%)
Reason for Delivery Before 34 weeks
Spontaneous 0 4 (25%)
Chorioamnionitis 1 (25%) 2 (25%)
Fetal Indications 3 (75%) 2 (25%)
Results expressed as Mean ± SD or N (%).
Fetal indications for delivery included abnormal fetal heart tracings (4 cases)
and fetal growth restriction with abnormal umbilical artery Doppler findings (1
case, placebo group).
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observations here are truly valid, randomized, double-
blinded, and placebo-controlled. Though we cannot
make much of the results in isolation, it is our expec-
tation that these 12 subjects ought to be included in
future metaanalyses and systematic reviews concerning
the use of 17P after PROM.
We have started a virtually identical study using the
FDA-approved formulation of 17P.
Conclusion
Premature termination of the study left us with a sample
too small to reach conclusions about efficacy of 17P
after PROM. Nonetheless, the results are valid and
ought to be included in any future metaanalyses or sys-
tematic reviews of this topic.
Availability of supporting data
Please refer to the section “Description of additional
data files” on the last page
Table 4 Selected other outcomes
17-Hydroxyprogesterone Caproate Placebo
(N = 4) (N = 8)
Maternal Management & Complications 3 (75%) 7 (87.5%)
Tocolysis in first 48 h 3 (75%) 5 (62.5%)
Antenatal Corticosteroids 4 (100%) * 8 (100%)
Cesarean Delivery 3 (75%) 5 (62.5%)
Preeclampsia or Gestational Hypertension 0 1 (12.5%)
Gestational Diabetes 0 2 (25%)
Chorioamnionitis 1 (25%) 1 (12.5%)
Sepsis 00
Neonatal Outcomes
Birthweight, gms 1328 ± 547 1288 ± 525
Total Hospital Stay, Days 42 ± 23 57 ± 48
NICU Stay, Days 42 ± 23 56 ± 48
Newborns with Congenital Anomaly** 1 (25%) 3 (37.5%)
Adverse Events Not Tabulated Elsewhere*** 0 1 (12.5%)
Data expressed as Mean ± SD or N (%)
NICU = Neonatal Intensive Care Unit
* One patient had received antenatal corticosteroids before PROM.
** One newborn in 17P group had ventriculoseptal defect and patent foramen ovale. Newborns with anomalies in the placebo group were 1 with bilateral
inguinal hernias and hypospadias, 1 with unilateral inguinal hernia, and 1 with umbilical hernia.
*** One newborn had congenital lobar emphysema
Table 3 Neonatal Morbidity and Mortality
17-Hydroxyprogesterone Caproate Placebo
(N = 4) (N = 8)
Composite Neonatal Morbidity 3 (75%) 7 (87.5%)
Perinatal Death
Stillbirth/Miscarriage 0 0
Neonatal Death 1 (25%) 1 (12.5%)
Respiratory Distress Syndrome 3 (75%) 7 (87.5%)
Sepsis, Culture-Proven 0 0
Pneumonia 00
Intraventricular hemorrhage, Grade 3 or 4 2 (50%) 0
Periventricular Leukomalacia 0 0
Necrotizing Enterocolitis 1 (25%) 0
Data expressed as N (%).
Composite Neonatal Morbidity = any one or more of the listed outcomes
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Role Personnel Institutions
Investigative Sites Rodney K Edwards MD, MS Obstetrix Medical Group, Phoenix Perinatal Associates
Melissa Ingersoll RN, CRC Banner Good Samaritan Medical Center, Phoenix, AZ
Ana Braescu, RN, MS Banner Desert Samaritan Medical Center, Phoenix, AZ
Banner Sun Health Research Institute (IRB)
Investigative Site C Andrew Combs MD, PhD Obstetrix Medical Group, San Jose
Kimberly Mallory RN Good Samaritan Hospital, San Jose, CA
Stacey Maguire RN Good Samaritan Hospital IRB
Investigative Sites Richard Porreco MD Obstetrix Medical Group of Colorado
Kent Heyborne MD Presbyterian Saint Luke’s Hospital, Denver, CO
Julie Rael RN Swedish Medical Center, Englewood, CO
Jeri Lech RN Presbyterian Saint Luke’s Hospital IRB
HCA-HealthONE IRB
Investigative Site David Luthy MD Obstetrix Medical Group of Washington
Tina Lopez RN Swedish Medical Center, Seattle, WA
Dawn Artis RN Swedish Medical Center IRB
Investigative Site George Lu MD Obstetrix Medical Group of Kansas City
Janice Etzenhouser RN Saint Luke’s Hospital of Kansas City, Kansas City, MO
Saint Luke’s Hospital of Kansas City IRB
Investigative Site Wilson Huang MD Center for Maternal Fetal Medicine
Judy Hancock MSN Sunrise Hospital, Las Vegas, NV
Sunrise Health IRB
Investigative Site Asad Sheikh MD Spectrum Health Maternal Fetal Medicine
Lori Oosterman BSN, RN Spectrum Health Hospital, Grand Rapids, MI
Alison Dutkiewicz RN Spectrum Health Hospital IRB
Investigative Site Michael Nageotte MD Obstetrix Medical Group, Southern California
Christine Preslicka BSN, RN Long Beach Memorial Medical Center, Long Beach, CA
MHS Research Administration (IRB)
Investigative Site Hugh Miller MD Obstetrix Medical Group of Arizona
Diane Mercer RN, CCRC Tucson Medical Center, Tucson, AZ
Tucson Medical Center IRB
Investigative Site David Lewis MD University of Cincinnati School of Medicine
Christine DeArmond RN University Hospital, Cincinnati, OH
University of Cincinnati IRB
Data & Safety Monitoring Board Reese Clark MD Pediatrix Medical Group CREQ, Piedmont, SC
Jay D Iams MD Ohio State University, Columbus, OH
Brian M Mercer MD MetroHealth Medical Center, Cleveland, OH
Barbara Marusiak, RN, MSc Pediatrix Medical Group, Phoenix, AZ
Biostatistics Anita Das, PhD Axistat, Inc., San Francisco, CA
Trial Administration Kimberly Maurel RN, MS Obstetrix Medical Group CREQ, Fountain Valley, CA
Kimberly Mallory RN Obstetrix Medical Group CREQ, Campbell, CA
Diana Abril RN Obstetrix Medical Group CREQ, Gilbert, AZ
Thomas J Garite MD Obstetrix Medical Group CREQ, Steamboat Springs, CO
C Andrew Combs MD, PhD Obstetrix Medical Group CREQ, Campbell, CA
CREQ = Center for Research, Education & Quality
IRB = Institutional Review Board
Description of Additional Data Files
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Page 7 of 9Additional material
Additional file 1: Protocol, version 1.6, 17P for PROM; 17-alpha-
hydroxyprogesterone caproate (17P) for prolongation of pregnancy
in women with preterm rupture of the membranes (PROM), double-
blind randomized clinical trial; Final version of protocol, approved
by IRB at each site.
Additional file 2: Data, 17P for PROM; Obstetrix Medical Group
data, 17-hydroxyprogesterone caproate for preterm rupture of
membranes; Results table, de-identified raw data for each
participant.
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